Cereno Scientific

“I am pleased to share that we are securing further IPR for drug candidate CS1 in the key market Japan, which is one of the largest global pharmaceutical markets. CS1’s growing patent portfolio is an important aspect of preparing the future commercial positioning, together with a strong clinical data set,” said Sten R. Sörensen, CEO at Cereno Scientific.

CS1’s second patent family is titled “Valproic Acid for the Treatment or Prevention of Pathological Conditions Associated With Excess Fibrin Deposition and/or Thrombus Formation” and has been assigned the patent number 7305605. The patent will be valid through 2035, with the possibility of patent extension of up to five years. The second patent family has previously been granted in Australia, Canada, Europe, Japan, Israel, Malaysia, Mexico, Russia, and the US.

Drug candidate CS1 is currently being evaluated in a Phase II study in PAH. Recently, positive findings from a data quality control review initiative of the ongoing study were released. The study is designed to randomize 30 PAH patients and the top-line result of the Phase II study is estimated to be reported in Q1 2024. More information about the study can be found on our website, https://cerenoscientific.com/press.

For further information, please contact:

Tove Bergenholt, Director IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 732-366 246

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.